Shares of clinical-stage biotech CytomX Therapeutics (NASDAQ: CTMX) surged by 43% this week following analyst Olivia Brayer from Cantor Fitzgerald initiating coverage with an overweight recommendation and a price target of $6 per share, suggesting potential for over a 100% upside. The rally began on Monday, reflecting strong investor interest in the cancer-focused drug developer.
